(Transcript) 2024 LeadershIP Conference Panel III: Architecting the Future: Call to Action for Innovation Policy

April 12, 2024

This transcript is from the 2024 LeadershIP Conference hosted at CSIS on April 9th, 2024. Watch the full video here.

(DOWNLOAD) LeadershIP 2024 – Panel 3 Transcript

Panel Description: There are several legislative proposals on the table today affecting IP, antitrust, and competition. Is more (or less) needed to establish a holistic innovation policy regime that prepares us for the future?

Speakers

Holly Fechner, Partner, Covington

Kate Hudson, Associate Vice President and Counsel for Government Relations and Public Policy, American Association of Universities

Judge Paul Michel, Court of Appeals for the Federal Circuit (Ret.)

Brian Pomper, Partner, Akin Gump

Judge Randall R. Rader, Former Chief Judge of U.S. Court of Appeals for the Federal Circuit (Ret.)

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor